IDT Australia Limited (AU:IDT)
ASX:IDT
Want to see AU:IDT full AI Analyst Report?
IDT Stock Chart & Stats
AU$0.05
>-AU$0.01(-1.87%)
At close: 4:00 PM EST
AU$0.05
>-AU$0.01(-1.87%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.11
Previous CloseN/A
Volume22.00K
Average Volume (3M)336.94K
Market Cap
AU$14.81M
Enterprise ValueAU$22.47M
Total Cash (Recent Filing)AU$1.93M
Total Debt (Recent Filing)AU$9.86M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding427,425,570
10 Day Avg. Volume373,970
30 Day Avg. Volume336,941
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)1.73
Price to Sales (P/S)1.92
P/FCF Ratio-5.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CDMO Fee-for-service Business ModelIDT's core CDMO fee-for-service model generates contract revenues tied to customers' manufacturing and development needs. This reduces product development risk for the company, gives multi-customer exposure across the pharma value chain, and supports predictable contractual revenue streams over the medium term.
Modest Recurring Revenue GrowthConsistent though modest top-line growth indicates sustained customer demand for manufacturing and development services. On a 2-6 month horizon this revenue traction supports operational utilization and the potential to scale fixed-cost absorption if the company converts more projects into commercial manufacturing.
Stable Equity Ratio / Asset BaseA stable equity ratio implies a tangible asset base that can underwrite operations and financing options. Combined with the note that debt remains relatively low versus industry standards, this balance-sheet footing provides resilience during cyclical pressure and preserves capacity to raise capital if needed.
Bears Say
Negative Operating And Free Cash FlowOngoing negative operating and free cash flows create structural liquidity pressure, limiting reinvestment in capacity or R&D and increasing reliance on external financing. Over months this undermines operational flexibility and raises execution risk for scaling or absorbing new contracts.
Loss-making With Declining MarginsSustained negative profitability and a falling gross margin indicate cost or pricing pressures that erode long-term margin sustainability. This reduces retained earnings, impairs the ability to self-fund growth, and makes margin recovery necessary for durable improvement in returns.
Rising Leverage And Negative ROEIncreasing leverage while generating negative ROE raises financial risk: higher interest and principal obligations with insufficient returns can strain solvency if cash flows don't improve. This combination reduces strategic flexibility and raises refinancing or covenant risks over the medium term.
IDT Australia Limited News
IDT FAQ
What was IDT Australia Limited’s price range in the past 12 months?
IDT Australia Limited lowest share price was AU$0.03 and its highest was AU$0.11 in the past 12 months.
What is IDT Australia Limited’s market cap?
IDT Australia Limited’s market cap is AU$14.81M.
When is IDT Australia Limited’s upcoming earnings report date?
IDT Australia Limited’s upcoming earnings report date is Aug 25, 2026 which is in 94 days.
How were IDT Australia Limited’s earnings last quarter?
IDT Australia Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
Is IDT Australia Limited overvalued?
According to Wall Street analysts IDT Australia Limited’s price is currently Overvalued.
Does IDT Australia Limited pay dividends?
IDT Australia Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on IDT Australia Limited dividends here
What is IDT Australia Limited’s EPS estimate?
IDT Australia Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IDT Australia Limited have?
IDT Australia Limited has 427,425,570 shares outstanding.
What happened to IDT Australia Limited’s price movement after its last earnings report?
IDT Australia Limited reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 25.581%.
Which hedge fund is a major shareholder of IDT Australia Limited?
Currently, no hedge funds are holding shares in AU:IDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IDT Australia Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IDT Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$58.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.80%
12-Months-Change
Fundamentals
Return on Equity
-29.05%
Trailing 12-Months
Asset Growth
-8.11%
Trailing 12-Months
Company Description
IDT Australia Limited
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. It offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. The company also provides project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in various dosage forms. In addition, it offers medicinal cannabis products, as well as various contract manufacturing services. The company was founded in 1975 and is headquartered in Boronia, Australia.
Technical Analysis
―
Little Green Pharma Ltd.
―
Medical Developments International Limited
―
―
Cronos Australia Ltd.
―
Options Prices
Currently, No data available
---